Signum Biosciences Inc. will collaborate with GlaxoSmithKline on Signum’s phosphatase screening technology and Phosphoprotein Phosphatase 2A (PP2A).

GSK and Signum will undertake an R&D collaboration to screen and identify PP2A targeted compounds including those bridging the link between PP2A methylation and tau hyperphosphorylation. 

“We will develop therapeutics using our phosphatase screening technology in an alliance that utilizes the expertise of both companies,” says Maxwell Stock, president of Signum Biosciences.

Release Date: Nov. 10, 2011
Source: Signum Biosciences, Inc.